TABLE 1.
Regenerative medicine therapy in Asian countries.
| Country | Type of RMT | Treatment | Cost | Success Rate | First Documented Date | References (s) |
|---|---|---|---|---|---|---|
| Japan | Stemchymal | Spinocerebellar ataxia | USD 5,862–58,620 | Not stated | Not mentioned | Awatin and Milne, (2021) |
| Allogeneic adipose-derived stem cells (eASC) injected intralesionally | Complex perianal fistulas in patients with Crohn’s disease | USD 4,000–8,000 | Not stated | Not mentioned | (Lu et al., 2019; Awatin and Milne, 2021) | |
| China | Gene therapy (Gendicine and Oncorine) | Neck cancer | USD 387 per injection | 30–40% complete response and 50–60% partial response with a total response rate of 90–96% | Gendicine: 2003 | Awatin and Milne, (2021) |
| Oncorine: 2005 | ||||||
| South Korea | Hearticellgram-AMI (therapeutic stem cells) | Myocardial infarction | USD 169,202 | Not stated | 2011 | Awatin and Milne, (2021) |
| Cupistem (MSC) | Reduce | USD 3,000–5,000 per treatment | Not stated | 2012 | (Ramezankhani et al., 2020; Awatin and Milne, 2021) | |
| Inflammation and regenerate | ||||||
| damaged joint | ||||||
| tissues (Crohn’s Fistula) |
USD, united states dollars.